• Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
Stock

Pharma giant Roche pledges $50 billion US investment in R&D, manufacturing

by April 22, 2025
by April 22, 2025

Swiss pharmaceutical giant Roche unveiled ambitious plans on Tuesday for a substantial $50 billion investment in the United States over the coming five years.

This significant commitment represents one of the largest recent inward investment declarations by a multinational corporation navigating the complexities of current US trade policies, including tariffs implemented under the Trump administration.

The comprehensive investment strategy is set to generate considerable employment opportunities across the country.

Roche detailed that the $50 billion infusion would lead to the creation of more than 12,000 new jobs.

This figure includes nearly 6,500 positions related to construction activities and an additional 1,000 permanent roles at newly established and expanded company facilities.

Strategic investment in a shifting trade environment

Roche’s announcement comes at a time when various global manufacturers, particularly within the pharmaceutical sector, are reassessing their supply chains and investment footprints in response to the Trump administration’s focus on tariffs and boosting domestic production.

This move mirrors a similar declaration earlier this month by fellow Swiss drugmaker Novartis, which committed to spending $23 billion on expanding and building new facilities within the United States.

Expanding US footprint: R&D and manufacturing focus

The scope of Roche’s investment is extensive, targeting key areas of its operations.

The company specified that the funds will support the development of new research and development (R&D) sites.

Furthermore, significant capital will be allocated to expanding existing manufacturing capabilities in several states, including Indiana, Pennsylvania, Massachusetts, and California.

This broad geographic spread underscores a deep commitment to enhancing Roche’s operational base within the US.

Aiming for net export status from the US

A key strategic outcome articulated by Roche is a fundamental shift in its US trade balance.

The company stated that once the new and expanded manufacturing capacities become fully operational, it anticipates exporting more medicines from the United States than it imports.

This signals a long-term vision for the US serving as a major global supply hub for the company’s products.

Underscoring the significance of the plan, Roche Chief Executive Thomas Schinecker emphasized the company’s dedication to the American market.

“Our investments of $50 billion over the next five years will lay the foundation for our next era of innovation and growth, benefiting patients in the US and around the world,” Schinecker said in a statement, framing the investment as crucial for future advancements and patient access globally.

The post Pharma giant Roche pledges $50 billion US investment in R&D, manufacturing appeared first on Invezz

0 comment
0
FacebookTwitterPinterestEmail

previous post
Here’s why I’d sell SCHD and JEPI ETFs and buy UTF instead
next post
Is Novo Nordisk falling behind Eli Lilly in the weight-loss drug race?

Related Posts

Opendoor stock plunges 21% after weak forecast: could...

August 7, 2025

Why Upstart stock tanked on Q2 earnings and...

August 7, 2025

GLD ETF analysis: is this gold fund on...

August 7, 2025

Asian markets open: Nikkei flat on US chip...

August 7, 2025

Europe markets open: Stocks rise; Maersk Q2 profit...

August 7, 2025

SoftBank posts strong quarterly profit of around $2.9B...

August 7, 2025

Trump and Putin to meet next week; White...

August 7, 2025

Is America really getting rich off tariff revenue?

August 7, 2025

Israel’s Leviathan gas field secures historic $35B export...

August 7, 2025

Trump’s tariff gamble on chips and drugs could...

August 6, 2025

Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

Recent Posts

  • How Telematics Is Reshaping Transportation

    August 7, 2025
  • What Families Gain at the Dinner Table

    August 7, 2025
  • Would Superman Bring Coffee to the Movies?

    August 7, 2025
  • Opendoor stock plunges 21% after weak forecast: could more downside be ahead?

    August 7, 2025
  • Why Upstart stock tanked on Q2 earnings and why it’s a raging buy here

    August 7, 2025
  • GLD ETF analysis: is this gold fund on the verge of a breakout?

    August 7, 2025

Editors’ Picks

  • 1

    Meta executives eligible for 200% salary bonus under new pay structure

    February 21, 2025
  • 2

    Walmart earnings preview: What to expect before Thursday’s opening bell

    February 20, 2025
  • 3

    New FBI leader Kash Patel tapped to run ATF as acting director

    February 23, 2025
  • 4

    Anthropic’s newly released Claude 3.7 Sonnet can ‘think’ as long as the user wants before giving an answer

    February 25, 2025
  • 5

    Nvidia’s investment in SoundHound wasn’t all that significant after all

    March 1, 2025
  • 6

    Cramer reveals a sub-sector of technology that can withstand Trump tariffs

    March 1, 2025
  • 7

    Elon Musk says federal employees must fill out productivity reports or resign

    February 23, 2025

Categories

  • Economy (2,112)
  • Editor's Pick (210)
  • Investing (185)
  • Stock (1,413)
  • About us
  • Contact us
  • Privacy Policy
  • Terms & Conditions

Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Portfolio Performance Today
  • Investing
  • Stock
  • Economy
  • Editor’s Pick
Copyright © 2025 Portfolioperformancetoday.com All Rights Reserved.

Read alsox

Amazon Alexa Fund expands AI investment strategy...

April 5, 2025

Asian markets open: Nikkei flat on US...

August 7, 2025

Asian stocks bleed on Monday: Nikkei crashes...

March 31, 2025